GP2013

BIOLOGICAL3 trials

Sponsors

Sandoz

Conditions

Follicular LymphomaIndolent B-cell Non-Hodgkin's LymphomaRheumatoid Arthritis

Phase 1

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

CompletedNCT01274182

SandozRheumatoid Arthritis

Start: 2011-01-31End: 2016-11-30Updated: 2018-01-24

GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma

CompletedNCT01933516

SandozIndolent B-cell Non-Hodgkin's Lymphoma

Start: 2013-05-31End: 2014-08-31Updated: 2018-07-26

Phase 3

GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)

CompletedNCT01419665

SandozFollicular Lymphoma

Start: 2011-12-01End: 2018-01-22Updated: 2021-05-14

Related Papers

Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study.

2017-07-1453 citations

A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis

Annals of the Rheumatic Diseases2017-06-2261 citations

Membrane Technology2016-05-01